CN111166686A - Hyaluronic acid toner - Google Patents
Hyaluronic acid toner Download PDFInfo
- Publication number
- CN111166686A CN111166686A CN201811336862.6A CN201811336862A CN111166686A CN 111166686 A CN111166686 A CN 111166686A CN 201811336862 A CN201811336862 A CN 201811336862A CN 111166686 A CN111166686 A CN 111166686A
- Authority
- CN
- China
- Prior art keywords
- hyaluronic acid
- toner
- cross
- concentration
- mass volume
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 36
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 36
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 36
- 239000000284 extract Substances 0.000 claims abstract description 25
- 239000010802 sludge Substances 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 13
- 239000007921 spray Substances 0.000 claims abstract description 10
- HDPLHDGYGLENEI-UHFFFAOYSA-N 2-[1-(oxiran-2-ylmethoxy)propan-2-yloxymethyl]oxirane Chemical compound C1OC1COC(C)COCC1CO1 HDPLHDGYGLENEI-UHFFFAOYSA-N 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract description 6
- 239000010410 layer Substances 0.000 abstract description 4
- 229920002385 Sodium hyaluronate Polymers 0.000 abstract description 2
- 230000004888 barrier function Effects 0.000 abstract description 2
- 238000004132 cross linking Methods 0.000 abstract description 2
- 229960004063 propylene glycol Drugs 0.000 abstract description 2
- 229940010747 sodium hyaluronate Drugs 0.000 abstract description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 abstract description 2
- 239000002344 surface layer Substances 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/965—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of inanimate origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a moisturizing spray toner comprising cross-linked hyaluronic acid or one of its salts in a concentration of 1% to 4% by mass volume, the cross-linking carried out providing the possibility of obtaining a gel based on cross-linked hyaluronic acid having a so-called cohesive structure; a concentration of the sea sludge extract in the form of an average size of less than or equal to 200 microns is between 5% and 60% by mass volume; the moisturizing spray toner has viscoelasticity such that tan δ at a frequency of 1Hz is less than or equal to 0.60. The moisturizing spray toner disclosed by the invention is mainly prepared from sea sludge extract, hydrolyzed hyaluronic acid, hyaluronic acid and propylene glycol, and is used for concentrating on water replenishing and moisturizing, and micromolecule hydrolyzed sodium hyaluronate penetrates through layers of barriers and penetrates into the bottom layer of the skin to inject source activity into the skin. The surface layer of the macromolecular hyaluronic acid locks water and preserves moisture, prevents water loss, replenishes water internally and preserves moisture externally.
Description
Technical Field
The invention belongs to the technical field of skin care products, and particularly relates to hyaluronic acid toner.
Background
Aging is a natural phenomenon faced by any individual, inevitably accompanied by reduction of cell activities of the human body, the completion of the metabolism function of the skin needs a large amount of water, like the human body, water shortage is the most important factor in skin aging, the water taken by the human body every day is poor in circulation to the face, the content is far from enough, and the water shortage of the skin causes many symptoms, such as death, skin growth, and the like, so that the skin needs to be refreshed. The toner, also called firming lotion, astringent, etc., has the effects of re-cleaning to restore the pH value of the skin surface, conditioning the stratum corneum, making the skin absorb better and preparing for the use of a care product.
Most of the skin toner in the existing formula has the effects of sterilization and astringency by adding alcohol, but can bring different degrees of stimulation to sensitive skin and dry skin, and as many as twenty-three kinds of raw materials are added in the existing formula, so that the skin toner can not be used by any skin.
Technical scheme
The invention mainly solves the technical problem of providing moisturizing spraying toner which is in the form of viscous viscoelastic gel and is characterized in that the toner comprises cross-linked hyaluronic acid or salt thereof, the concentration of the cross-linked hyaluronic acid or salt thereof is 1-3% by mass and volume, and the cross-linked hyaluronic acid is cross-linked with propylene glycol diglycidyl ether; the concentration of the sea sludge extract is 10% to 60% by mass volume, the sea sludge extract is in ultrafine form, having an average size of 10 μm or more and 200 μm or less, wherein the toner exhibits viscoelasticity such that tan δ at a frequency of 1Hz is 0.60 or less, and has been sterilized at a humid temperature.
Optionally, wherein the hyaluronic acid or one of its salts has a molecular weight between 2.5 x 105 dalton and 4 x 106 dalton.
Optionally, wherein the concentration of the cross-linked hyaluronic acid or one of its salts is between 1.5% and 2.5% mass volume percent.
Optionally, wherein the concentration of the sea sludge extract is between 10 and 50% mass volume percent.
Optionally, wherein the concentration of the sea sludge extract is between 20% and 40% mass volume percent.
The invention has the beneficial effects that:
the moisturizing spray toner disclosed by the invention is mainly prepared from sea sludge extract, hydrolyzed hyaluronic acid, hyaluronic acid and propylene glycol, and is used for concentrating on water replenishing and moisturizing, and micromolecule hydrolyzed sodium hyaluronate penetrates through layers of barriers and penetrates into the bottom layer of the skin to inject source activity into the skin. The surface layer of the macromolecular hyaluronic acid locks water and preserves moisture, prevents water loss, replenishes water internally and preserves moisture externally.
Examples
The following detailed description of the preferred embodiments of the present invention is provided to enable those skilled in the art to more readily understand the advantages and features of the present invention, and to clearly and unequivocally define the scope of the present invention.
Absorbable infill materials exist in the skin aesthetic market, for example, and can be made with products containing sea sludge extracts, these being suspended in an aqueous phase which may contain polymers like cellulose carboxymethyl cellulose, especially for use on the face, they exhibit a high level of biocompatibility, and for these products, few side effects or complications are reported, from the point of view of absorption, the rapid removal of the aqueous phase from the treatment area, the sea sludge extracts being degraded and metabolized by macrophages over time.
The object of the invention described below is to propose a new bioabsorbable moisturizing spray toner for cosmetic and aesthetic purposes, with specific characteristics of viscoelasticity, filling and long-term performance. The toner is characterized in that it is in the form of a particular cohesive viscoelastic gel, crosslinked hyaluronic acid or a salt thereof, at a concentration of between 1% and 4% (mass/volume), the crosslinking providing a gel based on crosslinked hyaluronic acid having a so-called cohesive structure, a concentration of sea sludge extract of between 5% and 60% (mass/volume), said sea sludge extract being in the form of an average size of less than or equal to 200 μm; the injectable sterile aqueous toner has viscoelastic properties such that TaN δ is less than or equal to 0.60 at a frequency of 1 Hz.
Surprisingly, according to the conditions of the present invention, it can be seen that this toner has a significant capacity to generate volume in the tissue over a long period of time, through a synergistic effect between the cross-linked hyaluronic acid and the sea sludge extract, which, from a mechanical point of view, greatly enhances the elasticity of the gel, so that it is able to generate volume by inducing a significant force/pressure on the tissue to correct the defective site to be whitened. Cross-linked hyaluronic acid itself provides viscoelastic properties, i.e. elasticity, but viscosity may also bring the gel consistency close to tissue, thus compensating for the very strong elasticity and lack of viscosity. On the other hand, crosslinked hyaluronic acid, under the conditions of the present invention, will greatly reduce the migration of the sea mud extract, remaining in the gel, due to the strong cohesion of the crosslinked hyaluronic acid. The strong limitation of the migration of the cohesive type (crosslinked hyaluronic acid with low absorption kinetics) offers the possibility of a gel with a long-term improved volume-forming capacity and of reducing side effects such as the appearance of so-called hard areas felt by the patient. Among the preferred salts of hyaluronic acid according to the invention, mention will be made of salts of hyaluronic acid with cations, for example monovalent or divalent salts, for example sodium, potassium, magnesium, calcium, manganese salts, sodium salts being particularly preferred. The cohesion of the gel based on cross-linked hyaluronic acid is a main and required specific feature of the present invention, the gel should not disperse rapidly when it is introduced into water, that is, the gel with non-viscous properties is called "biphasic" gel (gel based on cross-linked hyaluronic acid, which cannot sustain sea silt extract, thus avoiding migration).
The present invention generally comprises a concentration of cross-linked hyaluronic acid, or salt thereof, of between 1% and 4% (mass/volume), preferably between 1% and 3% (mass/volume). According to a particularly preferred alternative, the concentration of cross-linked hyaluronic acid or one of its salts is between 1.5% and 2.5% (mass/volume), or alternatively, the concentration of cross-linked hyaluronic acid or one of its salts may be between 1.5% and 3% (mass/volume) or between 1% and 2.5% (mass/volume), advantageously, the aqueous toner according to the invention comprises hyaluronic acid or one of its salts, the molecular mass of which is preferably between 2.5 × 105Da and 4 × 106 Da. According to a particularly preferred option, the molecular mass is between 1X 106Da and 3X 106Da, and in addition the molecular mass is between 1X 106Da and 2.5X 106Da, or between 2.5X 105Da and 3X 106 Da. The compounds of sea sludge extract have been used as biomaterials in various medical products for many years, the present invention generally comprising a concentration of sea sludge extract of between 5 and 60% (mass/volume), preferably between 10 and 50% (mass/volume), preferably between 20 and 40% (mass/volume), the sea sludge extract having an average size of less than or equal to 200 μm, preferably less than 50 μm, preferably greater than 10 μm. It has been observed that the viscosity and elastic properties of the formulations of the invention are best when the parameter TaN δ or TaN δ corresponding to the ratio [ viscosity modulus G ]/elastic modulus G' is less than or equal to 0.60, P, at a frequency of 1Hz, which can be referred to as less than or equal to 0.58. It has turned out that the elastic properties of the toner according to the invention with respect to its viscosity should be sufficiently large to be able to avoid sedimentation of the sea sludge extract.
Another object of the invention is to have a better life time compared to the formulations of the prior art, a better aesthetic effect is obtained by the capacity of the cross-linked hyaluronic acid to maintain the sea sludge extract in the injection zone for a long time and the capacity of the sea sludge extract to impart remarkable mechanical/rheological properties, so that the gain in skin lightening in the clinical situation of the toner according to the invention may be several months. On the other hand, the ability of sea mud extract to stimulate endogenous collagen production is an important factor of the present invention, and slow absorption of products in the tissue will be accompanied by collagen production (volume and elasticity production), which will provide the possibility of long-term participation in whitening.
The sequence of the above embodiments is only for convenience of description and does not represent the advantages and disadvantages of the embodiments.
Finally, it should be noted that: the above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some technical features may be equivalently replaced; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions of the embodiments of the present invention.
Claims (5)
1. A moisturizing spray toner in the form of a viscous viscoelastic gel, characterized in that the toner comprises cross-linked hyaluronic acid or a salt thereof at a concentration of 1% to 3% by mass volume, the cross-linked hyaluronic acid being cross-linked with propylene glycol diglycidyl ether; the concentration of the sea sludge extract is 10% to 60% by mass volume, the sea sludge extract is in ultrafine form, having an average size of 10 μm or more and 200 μm or less, wherein the toner exhibits viscoelasticity such that tan δ at a frequency of 1Hz is 0.60 or less, and has been sterilized at a humid temperature.
2. The moisturizing spray toner of claim 1, wherein: wherein the hyaluronic acid or one of its salts has a molecular weight between 2.5 x 105 dalton and 4 x 106 dalton.
3. The moisturizing spray toner of claim 1, wherein: wherein the concentration of the cross-linked hyaluronic acid or one of its salts is between 1.5% and 2.5% mass volume percent.
4. The moisturizing spray toner of claim 1, wherein: wherein the concentration of the sea sludge extract is between 10 and 50% mass volume percent.
5. The moisturizing spray toner of claim 1, wherein: wherein the concentration of the sea sludge extract is between 20% and 40% mass volume percent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811336862.6A CN111166686A (en) | 2018-11-12 | 2018-11-12 | Hyaluronic acid toner |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811336862.6A CN111166686A (en) | 2018-11-12 | 2018-11-12 | Hyaluronic acid toner |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111166686A true CN111166686A (en) | 2020-05-19 |
Family
ID=70617592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811336862.6A Pending CN111166686A (en) | 2018-11-12 | 2018-11-12 | Hyaluronic acid toner |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111166686A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3769750A1 (en) * | 2019-07-24 | 2021-01-27 | Amorepacific Corporation | A hyaluronic acid composition for external use on skin and its use |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104703582A (en) * | 2012-10-08 | 2015-06-10 | 安特易斯有限公司 | Sterile aqueous formulation for injection comprising cross-linked hyaluronic acid and hydroxyapatite for cosmetic use |
-
2018
- 2018-11-12 CN CN201811336862.6A patent/CN111166686A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104703582A (en) * | 2012-10-08 | 2015-06-10 | 安特易斯有限公司 | Sterile aqueous formulation for injection comprising cross-linked hyaluronic acid and hydroxyapatite for cosmetic use |
Non-Patent Citations (1)
| Title |
|---|
| 山东福瑞达生物工程有限公司: "颐莲玻尿酸补水喷雾", 《国产非特殊用途化妆品备案信息服务平台》, 16 July 2018 (2018-07-16), pages 1 - 2 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3769750A1 (en) * | 2019-07-24 | 2021-01-27 | Amorepacific Corporation | A hyaluronic acid composition for external use on skin and its use |
| CN112294690A (en) * | 2019-07-24 | 2021-02-02 | 株式会社爱茉莉太平洋 | Hyaluronic acid skin external preparation composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6995946B2 (en) | Dermal filler composition containing antioxidants | |
| CN104703582B (en) | Sterile aqueous formulation for injection comprising cross-linked hyaluronic acid and hydroxyapatite for cosmetic use | |
| AU2013276343B2 (en) | Composition, in an aqueous medium, including at least one hyaluronic acid and at least one sucrose octasulphate water-soluble salt | |
| JP6721584B2 (en) | Skin filler based on cross-linked hyaluronic acid and carboxymethyl cellulose lubricant | |
| JP5642388B2 (en) | Hyaluronic acid gel graft mixture for injection | |
| CN102196805B (en) | Heat sterilised injectable composition of hyaluronic acid or one of the salts thereof, polyols and lidocaine | |
| JP6946323B2 (en) | Modified hyaluronic acid, how it is made, and their use | |
| EP3125961B1 (en) | Polysaccharide soft tissue fillers with improved persistence | |
| BR112015031026B1 (en) | method for crosslinking hyaluronic acid or one of its salts or other biocompatible polymers; method for preparing an injectable hydrogel; hydrogel; kit and use | |
| JP2014510590A (en) | Composition comprising a filler product and at least one bioabsorbable and biodegradable silica-based material | |
| EA024569B1 (en) | Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions | |
| KR20220048906A (en) | Filler compositions | |
| EP2766424B1 (en) | Synthesis of an injectable multiphasic gel containing free and cross-linked monophasic hyaluronic acid and biphasic hyaluronic acid combined with hydroxyapatite with microencapsulated hyaluronidase inhibitor. | |
| JP2024144774A (en) | Cosmetic/dermatological compositions | |
| KR20150065861A (en) | Modified hyaluronic acid derivatives and use thereof | |
| CN111166686A (en) | Hyaluronic acid toner | |
| FR2919999A1 (en) | Cosmetic/pharmaceutical composition, useful to treat e.g. loss of dermal/epidermal volume, for filling depressions on skin surface and to treat wrinkles, and/or restore facial fullness, comprises hyaluronic acid and divalent cation | |
| KR102097933B1 (en) | Hyaluronic acid formulation containing pyruvate | |
| KR101917026B1 (en) | Cosmetic composition for skin wrinkle improvement and prevention | |
| RU2833246C2 (en) | Method of making dermal filler and preparing thereof for use | |
| KR102348467B1 (en) | A method for manufacturing a filler containing dna fraction and the filler prepared therefrom | |
| Devi et al. | Significance of hyaluronic acid in the biomedical field: A review | |
| Alsoufi | New and Innovative Developments in Hyaluronic Acid Fillers for Lip Enhancement and Contouring. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200519 |
|
| WD01 | Invention patent application deemed withdrawn after publication |